United States v. Oakland Cannabis Buyers' Cooperative

This article is general information, not legal advice. Laws change; check current rules with official sources or a lawyer.

Background

In 1996, California voters passed Proposition 215, the Compassionate Use Act, permitting patients to possess and use cannabis with a physician's recommendation ^[1]. The Oakland Cannabis Buyers' Cooperative (OCBC) was established shortly after to distribute cannabis to qualifying patients under this new state authorization ^[2].

In January 1998, the United States Department of Justice sued OCBC and several similar California dispensaries in federal district court, seeking an injunction under the Controlled Substances Act (CSA), which classifies cannabis as a Schedule I substance and prohibits its manufacture and distribution ^[2]. The district court granted the injunction. OCBC continued to operate, was held in contempt of court, and then filed a motion asking the court to modify the injunction to permit distribution to patients with serious medical conditions. When the district court refused, OCBC appealed to the Ninth Circuit Court of Appeals, which reversed, holding that a 'medical necessity' defense was legally cognizable and could apply to protect cannabis distribution for seriously ill patients with no viable legal alternative ^[2]. The government appealed to the Supreme Court.

The Legal Question

The narrow issue presented: does the Controlled Substances Act permit a medical necessity defense to its prohibitions on manufacturing and distributing cannabis? Strong evidence ^[2]

The common-law necessity defense allows a defendant to argue that violating a law was justified to prevent a greater harm. The Ninth Circuit had reasoned that for patients with serious medical conditions and no lawful alternative, distributing cannabis could qualify as a justified act under this traditional defense ^[2]. The Supreme Court accepted the case to decide whether federal law recognizes this exception.

The Court's Holding and Reasoning

Justice Clarence Thomas, writing for the majority, held that the Controlled Substances Act contains no medical necessity exception to its prohibitions on manufacturing and distribution ^[2].

The Court's principal reasoning:

• Congress placed cannabis in Schedule I, which by statutory definition requires that the substance have 'no currently accepted medical use in treatment in the United States' (21 U.S.C. § 812(b)(1)(B)).
• This legislative classification forecloses courts from finding sufficient medical benefit to justify a necessity defense.
• The only explicit medical exception in the CSA is for government-approved research. Congress knew how to write exceptions and chose not to write a broader one ^[2].

Justice John Paul Stevens, joined by Justices David Souter and Ruth Bader Ginsburg, concurred only in the judgment. Stevens agreed that the cooperative could not invoke necessity in that case, but argued the majority reached too far by suggesting that necessity could never apply to any CSA defendant, particularly individual patients rather than distributors seeking to supply others ^[2]. Justice Stephen Breyer was recused because his brother, a federal district judge, had presided over an earlier stage of the litigation ^[2].

What the Case Did and Did Not Decide

What was decided: Federal courts cannot grant equitable relief permitting cannabis distribution on grounds of medical necessity. The CSA's Schedule I classification is dispositive in federal court ^[2].

What was not decided: Whether state medical cannabis laws are preempted by federal law, whether individual patients (rather than commercial distributors) could ever assert a necessity defense, and whether the Commerce Clause permits federal regulation of cannabis produced and consumed wholly within a single state ^[2]. That last question reached the Supreme Court four years later in Gonzales v. Raich (2005), in which the Court answered it affirmatively, holding that the federal government may regulate intrastate cannabis activity Strong evidence ^[3].

The OCBC decision did not invalidate Proposition 215 or any state medical cannabis program. It established only that state medical cannabis authorizations provide no legal defense in federal proceedings.

Aftermath and Continuing Relevance

The Oakland Cannabis Buyers' Cooperative ceased cannabis distribution after the ruling but continued operating as an advocacy and patient-identification organization in Oakland ^[4].

The decision remains binding precedent. Federal prosecutors retain statutory authority to prosecute cannabis offenses regardless of state law. However, that authority has been constrained in practice by two developments:

Rohrabacher-Blumenauer Amendment: Beginning in fiscal year 2015, annual appropriations legislation has included a rider prohibiting the Department of Justice from expending funds to prevent states from implementing medical cannabis laws ^[5]. In United States v. McIntosh (2016), the Ninth Circuit Court of Appeals held that this amendment bars federal prosecution of individuals acting in substantial compliance with state medical cannabis law Strong evidence ^[6].

DOJ Enforcement Policy: Successive administrations have issued guidance deprioritizing federal prosecution of state-compliant cannabis operators, though no formal policy is uniformly binding across all field offices. These priorities can shift with changes in administration.

The core holding—that the CSA itself contains no medical exception—remains unoverruled. Should the DEA reschedule cannabis to a lower schedule (a process that has been the subject of administrative proceedings but remains ongoing as of October 2026), the statutory foundation on which Justice Thomas relied would change for that lower classification. However, the Court's reasoning about Schedule I substances would persist for any substance remaining on Schedule I.

Important Limitations and Disclaimers

This article is informational and not legal advice. Federal cannabis law is dynamic. Appropriations riders, DEA scheduling determinations, DOJ enforcement memos, state legislation, and court decisions can shift the legal landscape. The OCBC holding itself has not changed, but the practical application of federal cannabis law depends on enforcement policies and state law compliance.

If you have a specific question about your own legal situation involving cannabis, consult a licensed attorney in your jurisdiction.

Last verified: October 2026. As of this date, United States v. Oakland Cannabis Buyers' Cooperative remains good law and cannabis remains a Schedule I controlled substance under federal law. An administrative rescheduling proposal has been pending at the DEA, but cannabis has not been rescheduled.

Sources

How this page was made

Related

• Cannabis Buyers' Clubs of the 1990s — The informal dispensary networks that transformed cannabis from crime to state-legal medic...
• San Francisco Cannabis Buyers Club — The pioneering 1992 dispensary that shaped medical cannabis activism and policy.
• Federal Cannabis Law in the United States — How federal prohibition coexists with state legalization, and what may change.
• Leary v. United States (1969) — Supreme Court ruling that struck down the 1937 tax-stamp regime on self-incrimination grou...